nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentazocine—Abdominal distress—Methotrexate—esophageal cancer	0.102	0.102	CcSEcCtD
Pentazocine—Nodule—Methotrexate—esophageal cancer	0.0468	0.0468	CcSEcCtD
Pentazocine—Ulcer—Cisplatin—esophageal cancer	0.0265	0.0265	CcSEcCtD
Pentazocine—Ulcer—Capecitabine—esophageal cancer	0.0195	0.0195	CcSEcCtD
Pentazocine—Face oedema—Cisplatin—esophageal cancer	0.0176	0.0176	CcSEcCtD
Pentazocine—Irritability—Cisplatin—esophageal cancer	0.0174	0.0174	CcSEcCtD
Pentazocine—Cramp muscle—Cisplatin—esophageal cancer	0.0164	0.0164	CcSEcCtD
Pentazocine—Apnoea—Methotrexate—esophageal cancer	0.0162	0.0162	CcSEcCtD
Pentazocine—Hepatic function abnormal—Capecitabine—esophageal cancer	0.0154	0.0154	CcSEcCtD
Pentazocine—Sweating increased—Cisplatin—esophageal cancer	0.0153	0.0153	CcSEcCtD
Pentazocine—Abdominal discomfort—Cisplatin—esophageal cancer	0.0151	0.0151	CcSEcCtD
Pentazocine—Ulcer—Methotrexate—esophageal cancer	0.0145	0.0145	CcSEcCtD
Pentazocine—Diplopia—Capecitabine—esophageal cancer	0.0134	0.0134	CcSEcCtD
Pentazocine—Face oedema—Capecitabine—esophageal cancer	0.013	0.013	CcSEcCtD
Pentazocine—Irritability—Capecitabine—esophageal cancer	0.0128	0.0128	CcSEcCtD
Pentazocine—Urinary retention—Capecitabine—esophageal cancer	0.0128	0.0128	CcSEcCtD
Pentazocine—Visual impairment—Cisplatin—esophageal cancer	0.0121	0.0121	CcSEcCtD
Pentazocine—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.0121	0.0121	CcSEcCtD
Pentazocine—Tinnitus—Cisplatin—esophageal cancer	0.0117	0.0117	CcSEcCtD
Pentazocine—Flushing—Cisplatin—esophageal cancer	0.0117	0.0117	CcSEcCtD
Pentazocine—Sweating increased—Capecitabine—esophageal cancer	0.0113	0.0113	CcSEcCtD
Pentazocine—Abdominal discomfort—Capecitabine—esophageal cancer	0.0111	0.0111	CcSEcCtD
Pentazocine—Visual disturbance—Methotrexate—esophageal cancer	0.0105	0.0105	CcSEcCtD
Pentazocine—Muscle spasms—Cisplatin—esophageal cancer	0.0105	0.0105	CcSEcCtD
Pentazocine—Vision blurred—Cisplatin—esophageal cancer	0.0103	0.0103	CcSEcCtD
Pentazocine—Tremor—Cisplatin—esophageal cancer	0.0103	0.0103	CcSEcCtD
Pentazocine—Agranulocytosis—Capecitabine—esophageal cancer	0.00965	0.00965	CcSEcCtD
Pentazocine—Irritability—Methotrexate—esophageal cancer	0.00953	0.00953	CcSEcCtD
Pentazocine—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.009	0.009	CcSEcCtD
Pentazocine—Anaphylactic shock—Cisplatin—esophageal cancer	0.00895	0.00895	CcSEcCtD
Pentazocine—Visual impairment—Capecitabine—esophageal cancer	0.00895	0.00895	CcSEcCtD
Pentazocine—Erythema multiforme—Capecitabine—esophageal cancer	0.00878	0.00878	CcSEcCtD
Pentazocine—Tachycardia—Cisplatin—esophageal cancer	0.00873	0.00873	CcSEcCtD
Pentazocine—Tinnitus—Capecitabine—esophageal cancer	0.00866	0.00866	CcSEcCtD
Pentazocine—Hyperhidrosis—Cisplatin—esophageal cancer	0.00865	0.00865	CcSEcCtD
Pentazocine—Flushing—Capecitabine—esophageal cancer	0.00862	0.00862	CcSEcCtD
Pentazocine—Eosinophilia—Methotrexate—esophageal cancer	0.00855	0.00855	CcSEcCtD
Pentazocine—Anorexia—Cisplatin—esophageal cancer	0.00853	0.00853	CcSEcCtD
Pentazocine—Hypotension—Cisplatin—esophageal cancer	0.00836	0.00836	CcSEcCtD
Pentazocine—Chills—Capecitabine—esophageal cancer	0.00833	0.00833	CcSEcCtD
Pentazocine—Abdominal discomfort—Methotrexate—esophageal cancer	0.00828	0.00828	CcSEcCtD
Pentazocine—Paraesthesia—Cisplatin—esophageal cancer	0.00803	0.00803	CcSEcCtD
Pentazocine—Dyspnoea—Cisplatin—esophageal cancer	0.00798	0.00798	CcSEcCtD
Pentazocine—Dysgeusia—Capecitabine—esophageal cancer	0.00791	0.00791	CcSEcCtD
Pentazocine—Decreased appetite—Cisplatin—esophageal cancer	0.00778	0.00778	CcSEcCtD
Pentazocine—Muscle spasms—Capecitabine—esophageal cancer	0.00777	0.00777	CcSEcCtD
Pentazocine—Vision blurred—Capecitabine—esophageal cancer	0.00762	0.00762	CcSEcCtD
Pentazocine—Tremor—Capecitabine—esophageal cancer	0.00757	0.00757	CcSEcCtD
Pentazocine—Sweating—Methotrexate—esophageal cancer	0.00738	0.00738	CcSEcCtD
Pentazocine—Feeling abnormal—Cisplatin—esophageal cancer	0.00737	0.00737	CcSEcCtD
Pentazocine—Vertigo—Capecitabine—esophageal cancer	0.00726	0.00726	CcSEcCtD
Pentazocine—Syncope—Capecitabine—esophageal cancer	0.00725	0.00725	CcSEcCtD
Pentazocine—Agranulocytosis—Methotrexate—esophageal cancer	0.00718	0.00718	CcSEcCtD
Pentazocine—Loss of consciousness—Capecitabine—esophageal cancer	0.0071	0.0071	CcSEcCtD
Pentazocine—Hypertension—Capecitabine—esophageal cancer	0.00698	0.00698	CcSEcCtD
Pentazocine—Dry mouth—Capecitabine—esophageal cancer	0.00673	0.00673	CcSEcCtD
Pentazocine—Visual impairment—Methotrexate—esophageal cancer	0.00666	0.00666	CcSEcCtD
Pentazocine—Confusional state—Capecitabine—esophageal cancer	0.00665	0.00665	CcSEcCtD
Pentazocine—Hypersensitivity—Cisplatin—esophageal cancer	0.00659	0.00659	CcSEcCtD
Pentazocine—Erythema multiforme—Methotrexate—esophageal cancer	0.00653	0.00653	CcSEcCtD
Pentazocine—Shock—Capecitabine—esophageal cancer	0.00649	0.00649	CcSEcCtD
Pentazocine—Tinnitus—Methotrexate—esophageal cancer	0.00644	0.00644	CcSEcCtD
Pentazocine—Tachycardia—Capecitabine—esophageal cancer	0.00644	0.00644	CcSEcCtD
Pentazocine—Asthenia—Cisplatin—esophageal cancer	0.00642	0.00642	CcSEcCtD
Pentazocine—Hyperhidrosis—Capecitabine—esophageal cancer	0.00638	0.00638	CcSEcCtD
Pentazocine—Anorexia—Capecitabine—esophageal cancer	0.00629	0.00629	CcSEcCtD
Pentazocine—Chills—Methotrexate—esophageal cancer	0.0062	0.0062	CcSEcCtD
Pentazocine—Hypotension—Capecitabine—esophageal cancer	0.00616	0.00616	CcSEcCtD
Pentazocine—Diarrhoea—Cisplatin—esophageal cancer	0.00612	0.00612	CcSEcCtD
Pentazocine—Insomnia—Capecitabine—esophageal cancer	0.00597	0.00597	CcSEcCtD
Pentazocine—Paraesthesia—Capecitabine—esophageal cancer	0.00592	0.00592	CcSEcCtD
Pentazocine—Dysgeusia—Methotrexate—esophageal cancer	0.00589	0.00589	CcSEcCtD
Pentazocine—Dyspnoea—Capecitabine—esophageal cancer	0.00588	0.00588	CcSEcCtD
Pentazocine—Decreased appetite—Capecitabine—esophageal cancer	0.00573	0.00573	CcSEcCtD
Pentazocine—Vomiting—Cisplatin—esophageal cancer	0.00569	0.00569	CcSEcCtD
Pentazocine—Vision blurred—Methotrexate—esophageal cancer	0.00567	0.00567	CcSEcCtD
Pentazocine—Constipation—Capecitabine—esophageal cancer	0.00564	0.00564	CcSEcCtD
Pentazocine—Dermatitis—Cisplatin—esophageal cancer	0.00564	0.00564	CcSEcCtD
Pentazocine—Feeling abnormal—Capecitabine—esophageal cancer	0.00543	0.00543	CcSEcCtD
Pentazocine—Vertigo—Methotrexate—esophageal cancer	0.0054	0.0054	CcSEcCtD
Pentazocine—Nausea—Cisplatin—esophageal cancer	0.00531	0.00531	CcSEcCtD
Pentazocine—Confusional state—Methotrexate—esophageal cancer	0.00495	0.00495	CcSEcCtD
Pentazocine—Anaphylactic shock—Methotrexate—esophageal cancer	0.00491	0.00491	CcSEcCtD
Pentazocine—Hypersensitivity—Capecitabine—esophageal cancer	0.00486	0.00486	CcSEcCtD
Pentazocine—Hyperhidrosis—Methotrexate—esophageal cancer	0.00475	0.00475	CcSEcCtD
Pentazocine—Asthenia—Capecitabine—esophageal cancer	0.00473	0.00473	CcSEcCtD
Pentazocine—Anorexia—Methotrexate—esophageal cancer	0.00468	0.00468	CcSEcCtD
Pentazocine—Pruritus—Capecitabine—esophageal cancer	0.00467	0.00467	CcSEcCtD
Pentazocine—Hypotension—Methotrexate—esophageal cancer	0.00459	0.00459	CcSEcCtD
Pentazocine—Diarrhoea—Capecitabine—esophageal cancer	0.00451	0.00451	CcSEcCtD
Pentazocine—Insomnia—Methotrexate—esophageal cancer	0.00444	0.00444	CcSEcCtD
Pentazocine—Paraesthesia—Methotrexate—esophageal cancer	0.00441	0.00441	CcSEcCtD
Pentazocine—Dyspnoea—Methotrexate—esophageal cancer	0.00438	0.00438	CcSEcCtD
Pentazocine—Somnolence—Methotrexate—esophageal cancer	0.00436	0.00436	CcSEcCtD
Pentazocine—Dizziness—Capecitabine—esophageal cancer	0.00436	0.00436	CcSEcCtD
Pentazocine—Decreased appetite—Methotrexate—esophageal cancer	0.00427	0.00427	CcSEcCtD
Pentazocine—Vomiting—Capecitabine—esophageal cancer	0.00419	0.00419	CcSEcCtD
Pentazocine—Dermatitis—Capecitabine—esophageal cancer	0.00415	0.00415	CcSEcCtD
Pentazocine—Headache—Capecitabine—esophageal cancer	0.00413	0.00413	CcSEcCtD
Pentazocine—Feeling abnormal—Methotrexate—esophageal cancer	0.00405	0.00405	CcSEcCtD
Pentazocine—Nausea—Capecitabine—esophageal cancer	0.00392	0.00392	CcSEcCtD
Pentazocine—Hypersensitivity—Methotrexate—esophageal cancer	0.00362	0.00362	CcSEcCtD
Pentazocine—Asthenia—Methotrexate—esophageal cancer	0.00352	0.00352	CcSEcCtD
Pentazocine—Pruritus—Methotrexate—esophageal cancer	0.00347	0.00347	CcSEcCtD
Pentazocine—Diarrhoea—Methotrexate—esophageal cancer	0.00336	0.00336	CcSEcCtD
Pentazocine—Dizziness—Methotrexate—esophageal cancer	0.00325	0.00325	CcSEcCtD
Pentazocine—Vomiting—Methotrexate—esophageal cancer	0.00312	0.00312	CcSEcCtD
Pentazocine—Dermatitis—Methotrexate—esophageal cancer	0.00309	0.00309	CcSEcCtD
Pentazocine—Headache—Methotrexate—esophageal cancer	0.00308	0.00308	CcSEcCtD
Pentazocine—Nausea—Methotrexate—esophageal cancer	0.00292	0.00292	CcSEcCtD
